Tvardi Therapeutics, Inc.
TVRDNasdaq
$3.20
↑ +3.9%Jul 17 close · end-of-day
Price
1Y↓ -85.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$30.0M
Enterprise Value
$5.0M
P/E
—
P/S
—
P/B
2.1
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$15.4M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-106.4%
ROIC
—
Debt / Equity
—
Net Cash
$25.0M
Return 1Y
-86.7%
Company profile
Cara Therapeutics, Inc. focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe Pruritus associated with chronic kidney disease (CKD)
- CEO
- Christopher Posner
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 80
- Headquarters
- Connecticut
- Website
- caratherapeutics.com
Earnings
TVRD Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.73↓ -80.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $135.1M | $23.0M | $41.9M | $21.0M | $7.1M | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | $5.4M | -$89.1M | -$87.5M | -$121.5M | -$28.1M | -$26.7M |
| Net income | $8.4M | -$88.4M | -$85.5M | -$11.8M | -$29.4M | -$18.2M |
| Diluted EPS | $0.18 | -$1.74 | -$19.12 | -$26.26 | -$11.42 | -$3.26 |
| Operating cash flow | -$5.5M | -$60.1M | -$78.7M | -$92.1M | -$18.3M | -$23.5M |
| Free cash flow | -$5.8M | -$60.1M | -$78.8M | -$94.5M | -$19.4M | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 4.0% | -386.8% | -209.1% | -579.4% | -393.8% | — |
| Net margin | 6.2% | -384.1% | -204.2% | -56.5% | -411.9% | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $991,000.00 | $2.6M | $1.5M | $2.6M | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$7.2M | -$5.7M | $14.4M | -$4.4M | -$8.9M | -$5.9M | -$7.6M | -$7.1M |
| Net income | -$7.0M | -$5.5M | -$12.7M | -$9.6M | $4.2M | -$5.5M | -$7.3M | -$6.8M |
| Diluted EPS | -$2.71 | -$2.14 | $13.67 | -$3.72 | -$1.00 | -$0.59 | $2.05 | -$0.73 |
| Operating cash flow | $23.6M | -$6.7M | -$4.8M | -$7.7M | -$5.9M | -$4.3M | -$5.7M | -$5.9M |
| Free cash flow | $23.4M | -$6.7M | -$4.8M | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -724.6% | -222.1% | 990.8% | -169.5% | — | — | — | — |
| Net margin | -703.8% | -215.7% | -873.5% | -372.9% | — | — | — | — |
Company news
Jul 9, 2026
Jul 8, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.